精准医学杂志2025，Vol.40Issue(4)：326-330,5.DOI:10.13362/j.jpmed.202540074
达格列净联合百令胶囊治疗糖尿病肾病患者的有效性及安全性评价
Efficacy and safety of dapagliflozin combined with Bailing Capsule in treatment of patients with dia-betic kidney disease
摘要
Abstract
Objective To investigate the efficacy and safety of dapagliflozin combined with Bailing Capsule in the treat-ment of patients with diabetic kidney disease(DKD).Methods A total of 1 162 patients with early-stage DKD who were admit-ted to The Affiliated Hospital of Qingdao University from January 2019 to December 2023 were enrolled,and after propensity score matching was performed to balance intergroup covariates,the patients were divided into control group(dapagliflozin monotherapy)and combination group(dapagliflozin+Bailing Capsule)according to their treatment modality,with 417 patients in each group.The two groups were compared in terms of clinical outcome,blood glucose parameters,renal function parameters,safety indicators(liver function and routine blood test results),and the incidence rate of adverse events after 12 months of treatment.Results After 12 months of treatment,the combination group had a significantly better clinical outcome than the control group(Z=2.919,P＜0.05);the combination group had reductions in the levels of fasting plasma glucose,2 hour postprandial glucose,and HbA1c after treatment,with significantly greater reductions in these indicators compared with the control group(t=41.91-59.57,P＜0.05).The combination group had significant reductions in serum creatinine,blood urea nitrogen,24 hour urinary pro-tein,and urinary albumin excretion rate after treatment,with significantly greater reductions in these indicators compared with the control group(t=12.51-154.9,P＜0.05).After 12 months of treatment,liver function parameters and routine blood test results remained within normal ranges in both groups,and there were no significant differences between the two groups in the incidence rates of adverse events such as hypoglycemia and urinary tract infection(P＞0.05).Conclusion Dapagliflozin combined with Bailing Capsule can significantly reduce the level of blood glucose and improve renal function parameters in patients with DKD,with a better clinical effect than dapagliflozin monotherapy and with a favorable safety profile.关键词
糖尿病肾病/中西医结合疗法/钠-葡萄糖共转运蛋白2抑制剂/百令胶囊/倾向性评分/治疗结果/达格列净Key words
Diabetic nephropathies/Integrated chinese traditional and western medicine therapy/Sodium-glucose trans-porter 2 inhibitors/Bailing Capsule/Propensity score/Treatment outcome/Dapagliflozin分类
医药卫生引用本文复制引用
隋营营,周泉,韩亚斐,孙加琳,韩志武..达格列净联合百令胶囊治疗糖尿病肾病患者的有效性及安全性评价[J].精准医学杂志,2025,40(4):326-330,5.基金项目
山东省中医药科技重点项目(Z-2022076) （Z-2022076）
